Multiple Myeloma Posts on Medivizor
Navigation Menu

Multiple Myeloma Posts on Medivizor

Recommending bortezomib in multiple myeloma patients with poor kidney function

Posted by on Aug 10, 2018 in Multiple Myeloma | 0 comments

In a nutshell This paper studied the effect of recommending bortezomib as the first drug to use for multiple myeloma in patients with poor kidney function. This study concluded that after bortezomib became the recommended drug, there was an increase in the number of patients who did not require dialysis. Some background Up to 50% of patients with...

Read More

Evaluating cardiovascular safety of carfilzomib in patients with relapsed or refractory multiple myeloma

Posted by on Aug 10, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the cardiovascular (heart and blood vessels) safety of carfilzomib (Kyprolis) in patients with relapsed or refractory (does not respond to treatment) multiple myeloma. This study concluded that the benefits of carfilzomib outweighed its risks. Some background Multiple myeloma is a type of cancer of the bone...

Read More

Allogeneic transplant for multiple myeloma

Posted by on Jul 25, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study examined the role of allogeneic hematopoietic stem cell transplantation in multiple myeloma. The study determined that allogeneic stem cell transplant is feasible for patients who have previously received other treatment. Some background Survival of patients with multiple myeloma has improved with the development of new...

Read More

Using focal lesions seen on PET-CT to monitor outcome in multiple myeloma

Posted by on Jul 18, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study examined the use of PET-CT imaging to monitor response to treatment for multiple myeloma. The study concluded that treatment to suppress focal lesions seen on PET-CT is an important goal for newly diagnosed patients. Some background One way to improve outcomes in multiple myeloma is to customize treatment based on the...

Read More

What is the benefit of adding ixazomib to lenalidomide and dexamethasone for relapsing/refractory multiple myeloma?

Posted by on Jul 3, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the effects of adding ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone (Dexasone) for patients with unresponsive multiple myeloma. The main finding was that patients receiving ixazomib plus lenalidomide and dexamethasone survived longer without worsening of cancer (progression-free...

Read More

Bone protection treatment in multiple myeloma

Posted by on Jun 27, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study examined the use of bisphosphonate treatment for bone protection in patients with multiple myeloma. This study concluded that many patients do not receive adequate bone protection. Some background In multiple myeloma, bones are commonly affected, leading to bone destruction. Bisphosphonates are a group of drugs that prevent...

Read More

Carfilzomib – once weekly or twice weekly to treat unresponsive multiple myeloma?

Posted by on Jun 10, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the safety and effectiveness of two different doses of carfilzomib (Kyprolis) for patients with relapsed or refractory multiple myeloma. This study concluded that once weekly carfilzomib is safe and more effective than the twice weekly dose for these patients. Some background Multiple myeloma is a type of cancer...

Read More